Form 4 for IDXX Idexx Laboratories
Accepted 2022-02-16 00:00:00 ET · period of report 2022-02-14 · accession 0001567619-22-004784 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-02-16 | 2022-02-14 | IDXX | MCKEON BRIAN P | CFO, Executive VP | M - OptEx | $0.00 | +2,085 | 28.2K | +8% | $0 |
| D | 2022-02-16 | 2022-02-14 | IDXX | MCKEON BRIAN P | CFO, Executive VP | F - Tax | $505.53 | -964 | 27.4K | -3% | -$487.3K |
| DM | 2022-02-16 | 2022-02-14 | IDXX | MCKEON BRIAN P | CFO, Executive VP | M - OptEx | — | -2,085 | 6,411 | -25% | — |
| DM | 2022-02-16 | 2022-02-14 | IDXX | MCKEON BRIAN P | CFO, Executive VP | A - Grant | — | +11.9K | 10.5K | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-14 | M | A | 435 | $0.00 | 27,725.64 | D | — | — | |
| 2 | Common | Common Stock | 2022-02-14 | M | A | 253 | $0.00 | 28,411.64 | D | — | — | |
| 3 | Common | Common Stock | 2022-02-14 | F | D | 964 | $505.53 | 27,447.64 | D | — | — | |
| 4 | Common | Common Stock | 2022-02-14 | M | A | 505 | $0.00 | 27,290.64 | D | — | — | |
| 5 | Common | Common Stock | 2022-02-14 | M | A | 459 | $0.00 | 26,785.64 | D | — | — | (F1) Includes 10 shares purchased under the Issuer's Employee Stock Purchase Plan on December 31, 2021. |
| 6 | Common | Common Stock | 2022-02-14 | M | A | 433 | $0.00 | 28,158.64 | D | — | — | |
| 7 | Derivative | Restricted Stock Unit | 2022-02-14 | M | D | 253 | — | 4,785 | D | — · — to — | 253 Common Stock | (F10) Not applicable. (F9) Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. |
| 8 | Derivative | Restricted Stock Unit | 2022-02-14 | M | D | 433 | — | 5,038 | D | — · — to — | 433 Common Stock | (F10) Not applicable. (F8) Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. |
| 9 | Derivative | Restricted Stock Unit | 2022-02-14 | M | D | 435 | — | 5,471 | D | — · — to — | 435 Common Stock | (F10) Not applicable. (F7) Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. |
| 10 | Derivative | Restricted Stock Unit | 2022-02-14 | M | D | 505 | — | 5,906 | D | — · — to — | 505 Common Stock | (F10) Not applicable. (F6) Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. |
| 11 | Derivative | Restricted Stock Unit | 2022-02-14 | M | D | 459 | — | 6,411 | D | — · — to — | 459 Common Stock | (F10) Not applicable. (F5) Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2018. |
| 12 | Derivative | Restricted Stock Unit | 2022-02-14 | A | A | 1,212 | — | 6,870 | D | — · — to — | 1,212 Common Stock | (F10) Not applicable. (F4) Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. |
| 13 | Derivative | Incentive Stock Option (right-to-buy) | 2022-02-14 | A | A | 197 | — | 197 | D | $505.53 · — to 2032-02-13 | 197 Common Stock | (F10) Not applicable. (F3) Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on the fourth anniversary of the date of grant. |
| 14 | Derivative | Non-Qualified Stock Option (right-to-buy) | 2022-02-14 | A | A | 10,502 | — | 10,502 | D | $505.53 · — to 2032-02-13 | 10,502 Common Stock | (F10) Not applicable. (F2) Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2023. |